YU61398A - Derivati tiazola - Google Patents
Derivati tiazolaInfo
- Publication number
- YU61398A YU61398A YU61398A YU61398A YU61398A YU 61398 A YU61398 A YU 61398A YU 61398 A YU61398 A YU 61398A YU 61398 A YU61398 A YU 61398A YU 61398 A YU61398 A YU 61398A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- cell
- tumors
- well
- thiazole derivatives
- variopus
- Prior art date
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Jedinjenja formule I kao i njihove farmaceutski korisne soli i estri, pri čemu R1, R2 i R3 imaju značenje dato u zahtevu 1, inhibirajući vezivanje adhezivnih proteina na površinu različitih tipova ćelija i u skladu sa tim utiču na ćelija-ćelija i ćelija-matrica interakcije. Mogu se koristiti u obliku farmaceutskih preparata za kontrolu ili prevenciju neoplazmi, metastaza tumora, rasta tumora, osteoporoze, Paget-ove bolesti, dijabetske retinopatije, makularne degeneracije, restenosisa koji prati vaskularnu intervenciju, psorijaze, artritisa, fibroze, otkazivanja bubrega kao i infekcija izazvanih virusima, bakterijama ili gljivicama.[Compounds of formula I as well as pharmaceutically useful salts and esters, whereas R1, R2 and R3 have the meaning given in claim 1, inhibit connection of adhesive proteins on the surface of variopus types of cells and in accordance with that they influence cell to cell and cell to matrix interactions. They can be used in the shape of pharmaceutical preparations for control or prevention of neoplasmus, methastasis of tumors, growth of tumors, osteoporosis, Paget s diseases, diabetic reinopatia, muscular degeneration, restenosis, following vascular intervention, psoriasis, arthritis, fibrosis, disfunction of kidneys as well as infections caused by viruses, bacterias and fungus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98100006 | 1998-01-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU61398A true YU61398A (sh) | 2001-12-26 |
Family
ID=8231229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU61398A YU61398A (sh) | 1998-01-02 | 1998-12-30 | Derivati tiazola |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6100282A (sh) |
| JP (1) | JP3113237B2 (sh) |
| KR (1) | KR100312901B1 (sh) |
| CN (1) | CN1080720C (sh) |
| AR (1) | AR014949A1 (sh) |
| AT (1) | ATE233746T1 (sh) |
| AU (1) | AU720618B2 (sh) |
| BR (1) | BR9900006A (sh) |
| CA (1) | CA2257328C (sh) |
| CO (1) | CO4990934A1 (sh) |
| DE (1) | DE69811844T2 (sh) |
| DK (1) | DK0928790T3 (sh) |
| ES (1) | ES2193471T3 (sh) |
| HK (1) | HK1020953A1 (sh) |
| HR (1) | HRP980645A2 (sh) |
| HU (1) | HUP9803040A3 (sh) |
| ID (1) | ID21936A (sh) |
| IL (1) | IL127785A (sh) |
| MA (1) | MA26591A1 (sh) |
| NO (1) | NO312067B1 (sh) |
| NZ (2) | NZ333591A (sh) |
| PE (1) | PE20000061A1 (sh) |
| PL (1) | PL330619A1 (sh) |
| PT (1) | PT928790E (sh) |
| RU (1) | RU2218337C2 (sh) |
| SG (1) | SG74686A1 (sh) |
| TR (1) | TR199802765A2 (sh) |
| UY (1) | UY25334A1 (sh) |
| YU (1) | YU61398A (sh) |
| ZA (1) | ZA9811925B (sh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2001004103A1 (en) | 1999-07-13 | 2001-01-18 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
| US6759425B2 (en) * | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| US6960605B2 (en) * | 2000-01-19 | 2005-11-01 | Alteon, Inc. | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| ES2291455T3 (es) * | 2001-03-12 | 2008-03-01 | Avanir Pharmaceuticals | Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular. |
| PE20030968A1 (es) * | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| AU2004263190A1 (en) * | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| CA2580725A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | Novel heterocyclic nf-kb inhibitors |
| US8716320B2 (en) * | 2006-07-21 | 2014-05-06 | Replidyne, Inc. | Antibacteriall heterocyclic ureas |
| US8148380B2 (en) | 2007-07-23 | 2012-04-03 | Crestone, Inc. | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds |
| US8293919B2 (en) * | 2007-07-23 | 2012-10-23 | Crestone, Inc. | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds |
| TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| CN102936257B (zh) * | 2012-08-30 | 2016-03-30 | 齐鲁工业大学 | 一类含银的噻唑西弗碱配合物的结构、制备和用途 |
| WO2019002074A1 (en) | 2017-06-29 | 2019-01-03 | Bayer Aktiengesellschaft | THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PRMT5 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2009155B (en) * | 1977-11-07 | 1982-07-21 | Leo Pharm Prod Ltd | Chemical compounds |
| FR2581063B1 (fr) * | 1985-04-30 | 1987-07-17 | Chauvin Blache Lab | Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique |
| JPS62123180A (ja) * | 1985-11-21 | 1987-06-04 | Otsuka Pharmaceut Factory Inc | ｐ−アミノフエノ−ル誘導体 |
| US5000775A (en) * | 1985-12-31 | 1991-03-19 | Monsanto Company | 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes |
| JPS6348873A (ja) * | 1986-08-19 | 1988-03-01 | Toshiba Corp | ガスレ−ザ発振装置 |
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| CA2037153A1 (en) * | 1990-03-09 | 1991-09-10 | Leo Alig | Acetic acid derivatives |
| FI922867A (fi) * | 1991-06-21 | 1992-12-22 | Tanabe Seiyaku Co | Dikarbonsyraderivat och foerfarande foer framstaellning av dem |
| US5294713A (en) * | 1991-08-23 | 1994-03-15 | Takeda Chemical Industries, Ltd. | 2-piperazinone compounds and their use |
| GB9125970D0 (en) * | 1991-12-06 | 1992-02-05 | Fujisawa Pharmaceutical Co | New compounds |
| US5514643A (en) * | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| JPH08337579A (ja) * | 1995-06-14 | 1996-12-24 | Fujisawa Pharmaceut Co Ltd | グアニジノチアゾ−ルおよびその抗潰瘍剤、ｈ２−受容体拮抗剤および抗菌剤としての用途 |
| JPH09295974A (ja) * | 1995-09-11 | 1997-11-18 | Nippon Nohyaku Co Ltd | アゾール誘導体、その用途及びその製造方法並びにその使用方法 |
| NZ299242A (en) * | 1995-09-11 | 1997-12-19 | Nihon Nohyaku Co Ltd | N-phenyl-n'-(phenyl substituted imidazol-5-yl, -oxazol-4-yl, and -thiazol-4-yl)urea derivatives |
| DE69624728T2 (de) * | 1995-12-29 | 2003-07-10 | Boehringer Ingelheim Pharma | Phenyl thiazol derivate mit antiherpesvirus eigenschaften |
| MA26487A1 (fr) * | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant . |
-
1998
- 1998-12-22 US US09/218,567 patent/US6100282A/en not_active Expired - Fee Related
- 1998-12-24 DE DE69811844T patent/DE69811844T2/de not_active Expired - Fee Related
- 1998-12-24 PT PT98124670T patent/PT928790E/pt unknown
- 1998-12-24 ES ES98124670T patent/ES2193471T3/es not_active Expired - Lifetime
- 1998-12-24 NZ NZ333591A patent/NZ333591A/xx unknown
- 1998-12-24 AT AT98124670T patent/ATE233746T1/de not_active IP Right Cessation
- 1998-12-24 NZ NZ333590A patent/NZ333590A/xx unknown
- 1998-12-24 DK DK98124670T patent/DK0928790T3/da active
- 1998-12-28 NO NO19986159A patent/NO312067B1/no unknown
- 1998-12-29 AR ARP980106723A patent/AR014949A1/es not_active Application Discontinuation
- 1998-12-29 HR HR98100006.0A patent/HRP980645A2/hr not_active Application Discontinuation
- 1998-12-29 IL IL12778598A patent/IL127785A/en not_active IP Right Cessation
- 1998-12-29 PE PE1998001293A patent/PE20000061A1/es not_active Application Discontinuation
- 1998-12-29 ZA ZA9811925A patent/ZA9811925B/xx unknown
- 1998-12-30 CA CA002257328A patent/CA2257328C/en not_active Expired - Fee Related
- 1998-12-30 HU HU9803040A patent/HUP9803040A3/hu unknown
- 1998-12-30 CO CO98077476A patent/CO4990934A1/es unknown
- 1998-12-30 MA MA25411A patent/MA26591A1/fr unknown
- 1998-12-30 PL PL98330619A patent/PL330619A1/xx not_active Application Discontinuation
- 1998-12-30 YU YU61398A patent/YU61398A/sh unknown
- 1998-12-30 TR TR1998/02765A patent/TR199802765A2/xx unknown
- 1998-12-30 AU AU96144/98A patent/AU720618B2/en not_active Ceased
- 1998-12-30 SG SG1998005978A patent/SG74686A1/en unknown
- 1998-12-31 UY UY25334A patent/UY25334A1/es not_active IP Right Cessation
- 1998-12-31 CN CN98125982A patent/CN1080720C/zh not_active Expired - Fee Related
- 1998-12-31 KR KR1019980063364A patent/KR100312901B1/ko not_active IP Right Cessation
-
1999
- 1999-01-04 ID IDP990001D patent/ID21936A/id unknown
- 1999-01-04 JP JP11000010A patent/JP3113237B2/ja not_active Expired - Fee Related
- 1999-01-04 BR BR9900006-7A patent/BR9900006A/pt not_active Application Discontinuation
- 1999-01-05 RU RU99100277/04A patent/RU2218337C2/ru not_active IP Right Cessation
- 1999-12-28 HK HK99106136A patent/HK1020953A1/xx not_active IP Right Cessation
-
2000
- 2000-03-15 US US09/526,033 patent/US6320054B1/en not_active Expired - Fee Related
-
2001
- 2001-06-11 US US09/878,704 patent/US6344562B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU61398A (sh) | Derivati tiazola | |
| NO924915D0 (no) | Sakkarinderivater med inhiberende virkning paa protolytiske enzymer | |
| AU6194694A (en) | Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments | |
| NO941677L (no) | Tetrazolderivater av gallesyrer, fremgangsmåter for fremstilling og deres anvendelse som legemiddel | |
| CA2381097A1 (en) | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | |
| AR024703A1 (es) | Benzazepinonas y quinazolinas | |
| MX9704988A (es) | Derivados de hidroxilamina utiles para mejorar la produccion del acompañante molecular y la preparacion de los mismos. | |
| WO1991017773A3 (de) | Neue protein-polykation-konjugate | |
| MY117785A (en) | New 3-aryl-2-hydroxypropionic acid derivatives i | |
| AU7121394A (en) | Boronic acid or borinic acid derivatives as enzyme stabilizers | |
| AU581442B2 (en) | 2-substituted-1, 3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them | |
| ATE84045T1 (de) | Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen. | |
| YU29201A (sh) | Derivati tiazola | |
| BR9707889A (pt) | Composto e seus sais, composição farmacêutica, utilização do composto e método de trasferência de ácido nucléico para células. | |
| CA2257322A1 (en) | Thiazole derivatives | |
| ATE74138T1 (de) | Heptanoyl-glu-asp-ala-amino-saeureimmunstimulanten. | |
| Kitagawa | Selective inhibition of macromolecular synthesis in transformed mouse cells by means of ATP-treatment | |
| JPS5771396A (en) | Preparation of coenzyme q10 | |
| AU2128892A (en) | N-substituted aminomethanediphosphonic acids | |
| AU2944100A (en) | Gene therapeutics | |
| Balińska et al. | Betaine-homocysteine methyltransferase in the fungus Aspergillusnidulans | |
| IE802418L (en) | ANTIALLERGIC AND ANTIULCER 1-OXO-1H-THIAZOLO (3,2-a)¹PYRIMIDINE-2-CARBOXAMIDES | |
| ES8504806A1 (es) | Procedimiento para la fabricacion de derivados de triazolo pirimidina | |
| CA2255748A1 (en) | Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders | |
| Ikeno et al. | Effects of prolonged parotid duct ligation, parotidectomy and acute hepatitis of rats on amylase activity |